Phosphorylation mediated structural and functional changes in pentameric ligand-gated ion channels: Implications for drug discovery by Talwar, Sahil & Lynch, Joseph W.
 1 
Phosphorylation mediated structural and functional changes in pentameric 
ligand-gated ion channels: Implications for drug discovery 
 Sahil Talwar 
1
 and Joseph W. Lynch  
1,2 
* 
 
1
Queensland Brain Institute and 
2
School of Biomedical Sciences, The University of Queensland St 
Lucia, Australia 4072. 
 
*Corresponding author: 
Prof. Joseph W. Lynch, 
Queensland Brain Institute, 
The University of Queensland, 
Brisbane, QLD 4072. 
Australia. 
Phone: +617 3346 6375 
Fax: +617 3346 6301 
Email: j.lynch@uq.edu.au 
 
Article type: Molecules in Focus 
Number of words: main text, 1970; abstract, 147. 
No of figures: 2 
No of tables: 1 
No of references: 33 
 
Keywords: Cys-loop receptor, pentameric ligand-gated ion channel, phosphorylation, 
conformational changes, drug discovery 
 
Abbreviations: 5-HT3R: 5-hydroxytryptamine type-3 receptor; CamKII: Ca
2+
/calmodulin-
dependent protein kinase; GABAAR: GABA type-A receptor; GlyR: glycine receptor; IPSC: 
inhibitory postsynaptic current; nAChR: nicotinic acetylcholine receptor; PKA: protein kinase A; 
PKC: protein kinase C; pLGIC: pentameric ligand-gated ion channel; PTK: protein tyrosine kinase; 
PGE2: prostaglandin type-E2; VCF, voltage clamp fluorometry. 
 
  
*Manuscript
 2 
Abstract 
 
Pentameric ligand-gated ion channels (pLGICs) mediate numerous physiological processes, 
including fast neurotransmission in the brain. They are targeted by a large number of clinically-
important drugs and disruptions to their function are associated with many neurological disorders. 
The phosphorylation of pLGICs can result in a wide range of functional consequences. Indeed, 
many neurological disorders result from pLGIC phosphorylation. For example, chronic pain is 
caused by the protein kinase A-mediated phosphorylation of α3 glycine receptors and nicotine 
addiction is mediated by the phosphorylation of α4- or α7-containing nicotinic receptors. A recent 
study demonstrated that phosphorylation can induce a global conformational change in a pLGIC 
that propagates to the neurotransmitter-binding site. Here we present evidence that phosphorylation-
induced global conformational changes may be a universal phenomenon in pLGICs. This raises the 
possibility of designing drugs to specifically treat disease-modified pLGICs. This review 
summarizes some of the opportunities available in this area. 
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1. Introduction  
 
The pentameric ligand-gated ion channel (pLGIC) family includes nicotinic acetylcholine 
receptors (nAChRs), GABAA receptors (GABAARs), glycine receptors (GlyRs) and 5-HT3 
receptors (5-HT3Rs). Although these receptors are involved in many physiological processes, they 
are probably best known for mediating fast neurotransmission in the nervous system. They have 
been implicated in numerous channelopathies with neurological manifestations and are pivotal 
pharmacological targets. For example, nAChRs play a clinical role in nicotine addiction and are 
therapeutic targets for Alzheimer’s disease and schizophrenia (Pollock et al., 2009); GABAARs are 
important clinical targets for epilepsy (Abramian et al., 2010), anxiety, addiction and anaesthesia 
(Song and Messing, 2005); GlyRs are emerging targets for chronic inflammatory pain (Harvey et 
al., 2004). 
Phosphorylation is well known to influence synaptic function by directly modulating pLGICs 
(Swope et al., 1999) Indeed, pLGIC phosphorylation has been implicated in various disorders such 
as nicotine addiction (Wecker et al., 2001), status epilepticus (Terunuma et al., 2008) and chronic 
pain (Harvey et al., 2004). Phosphorylation of pLGICs can elicit a wide variety of effects, ranging 
from alterations in the level of surface expression, synaptic targeting and receptor desensitization. 
Many of these effects are summarized in Table 1. Until recently, there have been few attempts to 
resolve the structural basis of these effects. By doing so, it may be possible to design drugs to 
specifically treat the consequences of pathological receptor modifications that lead to disease. This 
review summarizes some of the opportunities available in this area. 
 
2. Structure 
 
2.1. pLGIC architecture 
 
Functional pLGICs comprise pentameric assemblies of identical or different subunits (Fig. 1A). 
The five subunits together form a central water-filled pore that facilitates transmembrane ion flux 
(Fig 1B). Each subunit can be divided into three domains, an extracellular ligand-binding domain, 
four transmembrane helices (termed M1-M4) and a large intracellular M3-M4 domain which has a 
length and primary structure that varies enormously among pLGIC members (Fig. 1A). The 
extracellular domain predominantly comprises a twisted β-sheet sandwich with ligand-binding 
pockets located at the subunit interfaces. The principal (+) side of the pocket is lined by binding 
domain loops A, B and C and the complementary (–) side is lined by binding loops D, E and F (Fig. 
1A). The transmembrane α-helices form concentric rings around a central ion pore, which is 
directly lined by five M2 helices (Fig 1A).  
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2.2. Structure and importance of the M3-M4 cytoplasmic domain  
 
Unlike the extracellular and transmembrane domains, the M3-M4 domain is poorly conserved 
both in terms of length and amino acid sequence. Therefore, it is likely to exhibit structural 
variation. Low-resolution structural data suggest that the Torpedo nAChR M3-M4 domain forms a 
‘hanging basket’ type structure connecting the pore with the cytoplasm (Miyazawa et al., 1999). 
This structure incorporates a lateral ion permeation pathway (or portal) linking the cytoplasm with 
the inner vestibule at the base of the pore. Charged residues lining these portals influence the single 
channel conductance of nAChRs, GlyRs and 5HT3Rs (Peters et al., 2010). Interactions between the 
M3-M4 loop and other proteins or ions are well known to modulate pLGIC activity, assembly and 
trafficking (e.g., Luscher et al., 2011). These interactions are highly specific to different pLGIC 
subunits. The M3-M4 domain is also the only pLGIC region known to house phosphorylation sites.  
 
2.3. Receptor phosphorylation: structural changes induced by kinases?  
 
Phosphorylation results from the kinase-mediated covalent attachment of the γ-phosphate 
group of ATP to the hydroxyl group of serine, threonine or tyrosine (Fig. 1D). The best-
characterized protein kinases include cAMP dependent protein kinase A (PKA), protein kinase C 
(PKC) and protein tyrosine kinase (PTK). Of these, PKA and PKC phosphorylate both Ser and Thr 
residues and PTK (including Src family kinase) phosphorylates Tyr residues. Many other kinases 
also exist such as Ca
2+
/calmodulin-dependent protein kinases (CaMKII) which also phosphorylate 
both Ser and Thr residues (Swope et al., 1999, Davis et al., 2001). The consensus phosphorylation 
site for Ser/Thr or Tyr specificity is determined by the structure of the catalytic cleft of the kinase 
and the local interactions between the kinase cleft and protein phosphorylation site. This binding 
between the kinase and the receptor protein often provides additional binding interactions, and 
occasionally, provides allosteric regulation and localization to specific cellular compartments or 
structures (Ubersax and Ferrell, 2007). Phosphorylation can have many effects on pLGIC function, 
including alterations in open probability and desensitization, surface expression levels, turnover rate 
and synaptic targeting (Swope et al., 1999, Davis et al., 2001) (Fig. 1E).  
 
3.  Biological function 
 
3.1. Chronic inflammatory pain is mediated by phosphorylation of α3 GlyRs  
 
Perhaps the most direct evidence for phosphorylation-induced structural changes in a pLGIC, 
and its relationship with a disease, has emerged from studies on the α3 GlyR. This will now be 
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described in detail. Inflammatory pain is mediated by the production of prostaglandins in the spinal 
cord. Electrophysiological studies have identified prostaglandin E2 (PGE2) as the most active 
prostaglandin in the spinal cord, where it specifically inhibits glycinergic inhibitory postsynaptic 
currents (IPSCs) in lamina I and II nociceptive neurons (Ahmadi et al., 2002). This effect is 
mediated via activation of the EP2 receptor involves the activation of PKA. Although α3 GlyRs are 
generally sparsely expressed, they are highly expressed along with α1 subunits at glycinergic 
synapses in lamina I and II neurons (Harvey et al., 2004). As only α3 GlyRs are inhibited by PGE2 
via PKA-dependent phosphorylation at S346 in the M3-M4 domain, it was hypothesised that the α3 
subunit was modulated by PGE2 (Harvey et al., 2004). Although GlyR α3
-/-
 mice displayed no overt 
behavioural phenotype, normal and knockout mice responded similarly to non-painful tactile 
stimuli and acute inflammatory pain stimuli. However, chronic inflammation produced pain 
sensitisation in normal animals but not in the GlyR α3-/- animals (Harvey et al., 2004). Thus, PGE2 
induces chronic pain by phosphorylating, and inhibiting, α
glycinergic IPSCs in spinal pain sensory neurons, thereby ‘disinhibits’ them and increasing the 
likelihood of pain impulses being transmitted to the brain. Thus, drugs that potentiate (i.e., restore) 
α α -potentiating agents do exert potent analgesic 
effects in animal pain models. For example, synthetic cannabinoid derivatives modified to prevent 
their binding to CB1 or CB2 cannabinoid receptors exert potent analgesia via direct effects on α
GlyRs  (Xiong et al., 2012). 
Phosphorylation-induced conformational changes in the α3 GlyR have recently been probed 
using voltage clamp fluorometry (VCF) (Han et al., 2013). VCF takes advantage of the fact that 
changes in the quantum efficiency of small molecule fluorophores occur in response to changes in 
their chemical microenvironment. It involves introducing a cysteine into the domain of interest and 
covalently tagging it with a sulfhdryl-labeled fluorophore, often a rhodamine derivative. This 
technique enables one to probe conformational changes in protein domains of interest in real time. 
Using this approach, forskolin-induced PKA phosphorylation of Ser346 in the α3 GlyR cytoplasmic 
domain elicited a change in the glycine-induced fluorescence response of a label attached to R19’C 
in the M2-M3 linker or to N203C in loop C of the glycine-binding site (Fig. 2A). This effect was 
not observed if Ser346 was mutated to prevent its phosphorylation (Fig. 2B and 2C). Thus, 
phosphorylation exerts a global conformational change that propagates from S346 in the internal 
M3- -binding site, a distance of >80 Å. The experiments 
shown in Fig. 2 were performed in Xenopus oocytes where phosphorylation does not reduce  
GlyR current. However, when the same receptors are expressed in HEK293 cells, phosphorylation 
reduced current magnitude and produced a conformational change in the glycine-binding site (Han 
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et al., 2013). This conformational change appears to be unique because it is accompanied by an 
increase in both glycine sensitivity and the potency of the competitive antagonist, tropisetron (Han 
et al., 2013). These results raise the possibility of developing analgesic drugs to specifically target 
disease-affected receptors.  
 
3.2 Phosphorylation-mediated conformational and functional changes in other pLGICs 
 
Phosphorylation also appears to induce conformational changes in GABAARs. For example, 
PKC activators altered the efficacy of benzodiazepines and barbiturates in neuronal GABAARs 
(Gao and Greenfield, 2005). Another study reported that PKC activation reduced the amplitude of 
GABAergic IPSCs in a manner that was completely inhibited by pre-treatment with neurosteroids 
(Brussaard et al., 2000). Other studies suggest different PKC isoforms differentially affect 
GABAAR alcohol sensitivity (Song and Messing, 2005, Qi et al., 2007). Importantly, these later 
effects have been implicated in alcoholism. Several other examples of GABAAR subunit 
phosphorylation sites that have been linked to receptor functional changes and neurological disease 
are summarized in Table 1.  
Many neuronal nAChRs are also regulated by phosphorylation. For example, 
dephosphorylation of α7 nAChRs caused a rapid increase in acetylcholine-evoked current and 
alterations in α-bungarotoxin sites with no change in receptor surface expression (Wiesner and 
Fuhrer, 2006). 
Widely expressed in the brain, the α4β2 nAChRs are proposed to play a major role in the 
mechanisms that cause nicotine addiction. Another study reported that PKA phosphorylation at 
Ser467 in the M3-M4 domain increases the relative abundance of α4 available for assembly, which 
favoured the functional expression of low affinity α4β2 receptors (Bermudez and Moroni, 2006). In 
addition, previous studies had shown the possible functional significance of 
phosphorylation/dephosphorylation on α4β2 receptor desensitization at the Ser368 residue. 
Phosphorylation-mediated time course recovery from desensitization implicated different receptor 
conformations with continuous nicotine exposure leading to an irreversible desensitized 
conformation (reviewed in (Quick and Lester, 2002). Recently, a study by Pollock and colleagues 
reported a dual effect of PKC at multiple sites of α4 subunits associated with mature and immature 
receptors. Nicotine has been implicated as a chaperone to promote subunit assembly and stabilize 
the α4β2 receptors at the cell surface (Pollock et al., 2009). Other examples of neuronal nAChR 
subunit phosphorylation sites that have been linked to receptor functional changes and neurological 
disease (notably nicotine addiction and cognitive impairment) are summarized in Table 1. 
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Muscle nAChRs have also been demonstrated as phosphorylation targets.  PKA phosphorylates 
γ and δ subunits, PKC phosphorylates δ and α subunits and PTK phosphorylates β, γ and δ subunits 
(Swope et al., 1999). Phosphorylation of muscle nAChRs is related mainly to myasthenia gravis 
(Table 1).  
 
4.  Possible medical applications 
 
Here we demonstrate that neurological disorders can result from conformational changes 
induced by the ‘inappropriate’ phosphorylation of pLGICs. For example, PKA-mediated 
phosphorylation 3 GlyRs (which causes chronic pain) inhibits current and causes a global 
conformational change that changes the structure of the glycine-binding site (Han et al., 2013), and 
alcoholism can result from a phosphorylation-induced increase in ethanol sensitivity of 2-
containing GABAARs (Qi et al., 2007). We propose that in these and other neurological disorders, 
phosphorylation induces a global allosteric conformational change that alters the structure of 
orthosteric or allosteric binding sites. 
In classical allosteric theory, receptors are considered to exist in either inactive or active states 
and drugs that modify their function do so by stabilising one of these states (Nussinov and Tsai, 
2014). In reality the situation is much more complex with numerous states existing in unmodified 
receptors, and even more that can be induced via covalent modifications (such as phosphorylation) 
or protein-protein interactions. We suggest that an ideal therapeutic drug would bind specifically to 
a phosphorylated (disease-affected) receptor and promote a conformational change that specifically 
compensates for the deleterious effect of phosphorylation. As far as we are aware, no such drug has 
yet been developed for any receptor type. However, there is no reason why this should not be 
feasible given that phosphorylation is well known to modulate the ability of enzymes to bind 
specifically to their substrates.  
The aim of this brief commentary is to raise awareness of the fact that phosphorylation can 
cause global allosteric conformational changes in pLGICs and to suggest that these conformations 
could in principle be targeted by drugs with therapeutic potential. 
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Figure Legends 
 
Fig. 1. Structure and phosphorylation of pLGICs. (A) Side view of pentameric α3 GlyR homology 
model viewed parallel to the membrane showing five identical subunits, each colored differently. 
The large M3-M4 cytoplasmic loop is shown as a dashed line as its structure is not known. (B) Top 
down view of the same pentameric assembly showing the central pore and the (+) and (-) subunit 
interfaces. (C) Close-up side view of an extracellular domain subunit interface showing ligand-
binding loops A, B and C on the (+) side of the subunit interface and loops D, E and F on the (-) 
side of the interface. (D) Ion channel phosphorylation pathway. (i) Phosphorylation starts with the 
binding of ATP to the catalytic site of the protein kinase. (ii) Binding of ATP is followed by protein 
kinase binding to the substrate receptor. (iii) Followed by γ-phosphate transfer from ATP to Ser/Thr 
or Tyr of the receptor phosphorylation site. (iv) Following phosphorylation, kinase leaves the 
receptor with ADP bound, following which ADP is released. (E) Phosphorylation of pLGICs leads 
to many possible outcomes, some of which are indicated. 
 
Fig. 2. Phosphorylation-mediated conformational changes in the α3 GlyR expressed in Xenopus 
laevis oocytes. (A) Cartoon depicting location of labelled residues for VCF in the ligand-binding 
site (N203C; green), M2-M3 linker (R19’C; blue) and the phosphorylation site (S346G, magenta). 
(B) Example of EC50 glycine-induced current (I) and fluorescence (F) responses in fluorescently-
labelled α3-R19’C and α3-R19’C-S346G GlyRs before and after a 15 min forskolin (FSK) 
treatment and after a 15 min wash. Averaged results (right panel) reveal that forskolin inhibits 
glycine-mediated fluorescence responses only in α3 GlyRs containing a functional S346 
phosphorylation site. (C) Example and averaged data of saturating glycine- and strychnine-induced 
ΔI and ΔF responses in fluorescently-labelled α3-N203C and α3-N203C-S346G GlyRs before and 
after a 15 min forskolin treatment and after 15 min wash. Figure modified from Han et al. (2013). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 12 
 
 
 
 
 
 
 
 
 
Table 1: Effect of phosphorylation on pLGICs and their relevance to diseases. 
 
Receptor Subtype Phosphorylatio
n 
Site 
 
Protein 
Kinase 
Effect on Receptor 
Function 
Disease relevance Reference 
GlyR α3 S346 PKA Inhibition of glycinergic 
currents 
Chronic 
inflammatory pain 
(Harvey et al., 2004) 
 
 
 
 
 
 
 
 
 
 
 
 
 
GABAAR 
β1 
 
S409         PKA, 
       PKC 
Enhanced desensitization and 
prolonged deactivation  
Epilepsy (Hinkle and Macdonald, 
2003) 
 
 
 
 
 
β3 
 
S408, S409 
 
 
 
 
 
S383 
 
PKC 
 
 
PKC 
 
 
 
 
CamKII 
Alterations in cell surface 
expression. 
 
BDNF-mediated transient 
increase in receptor function 
followed by down regulation 
 
Rapid insertion of extrasynaptic 
receptors at the cell surface and 
enhanced tonic currents in 
hippocampus 
Status epilepticus 
 
 
Neuronal 
Excitotoxicity 
 
 
Neuropsychiatric 
disorders 
(Terunuma et al., 2008) 
 
 
(Jovanovic et al., 2004) 
 
 
 
(Saliba et al., 2012) 
 
 
 
 
 
γ2 
S327 
 
 
S343 
 
 
Y365, Y367 
PKC 
 
 
PKC 
 
 
     Src 
Alterations in ethanol and 
benzodiazepine sensitivity 
 
Increased amplitude of mIPSCs 
 
Increased postsynaptic receptor 
expression and enhanced 
frequency of hippocampal 
mIPSCs  
Alcoholism 
 
 
Alcoholism 
 
 
Spatial memory 
deficits 
 
(Qi et al., 2007) 
 
 
(Song and Messing, 
2005) 
 
 
(Tretter et al., 2009, 
Luscher et al., 2011) 
α4 
 
S443 PKC Increased cell surface stability 
and activity 
Temporal lobe 
epilepsy 
(Abramian et al., 2010) 
 
 
 
α7 
Y386, Y442 
 
 
 
Y386, Y442, 
Y317 
Src 
 
 
 
Src 
Increased current amplitudes 
with no change in surface 
receptor number 
 
Increased surface receptor 
numbers with no change in 
open probability 
 
 
 
Cognition and 
addiction 
 
 
 
(Charpantier et al., 2005) 
 
 
 
(Cho et al., 2005) 
 
 
 
 
 
 
 
 
 
 
 
 
nAChR 
(neuronal) 
 
 
 
 
 
 
 
α4 
S368 
 
 
  S365,S472,   
S491 
 
 
S467 
 
 
 
S550 
   PKC 
 
 
PKA 
 
 
PKA 
 
 
 
PKC 
Prolonged nicotine-induced 
desensitization 
 
Increased surface expression  
 
 
Favoured expression of low-
affinity receptors 
 
Dual action affecting mature 
receptors to stabilize the 
receptors at cell surface and 
increase transport of immature 
receptors from endoplasmic 
reticulum to membrane 
 
 
 
 
 
 
Nicotine addiction 
(Wecker et al., 2001) 
 
 
(Guo and Wecker, 2002) 
 
 
(Bermudez and Moroni, 
2006, Pollock et al., 
2009) 
 
(Pollock et al., 2009) 
 
 
 
β 
Y390 
 
 
Y355 
 
Src 
 
 
Src 
Decreased receptor turnover 
and metabolic stabilisation 
 
Enhanced desensitization and 
immobilization of the receptor 
 
 
Myasthenia gravis 
(Rudell and Ferns, 2013) 
 
 
(Tzartos et al., 1993) 
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nAChR 
(muscle) 
 
 
δ 
S361, S362 
 
 
Y372 
 
PKA 
 
 
Src 
Enhanced desensitization 
 
 
Stable localisation of the 
receptor during synaptogenesis 
 
 
 
Myasthenia gravis 
 
(Hoffman et al., 1994) 
 
 
(Wagner et al., 1991) 
γ S353, S354 PKA Enhanced desensitization (Hoffman et al., 1994) 
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